Insmed (NASDAQ:INSM) Given New $165.00 Price Target at Mizuho

Key Points

• Mizuho has raised its price target for Insmed from $130 to $165, indicating a potential upside of 35.25% from the last closing price.
• Multiple analysts have also increased their ratings and price targets, with most ratings categorized as a "Moderate Buy."
• Insmed reported a revenue of $107.42 million for the last quarter but posted an earnings per share loss of ($1.70), missing consensus estimates.

Insmed (NASDAQ:INSM - Get Free Report) had its target price increased by research analysts at Mizuho from $130.00 to $165.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. Mizuho's target price would suggest a potential upside of 35.25% from the company's previous close.

Other equities analysts also recently issued reports about the stock. Bank of America increased their price objective on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. JPMorgan Chase & Co. raised their target price on Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada reissued an "outperform" rating and set a $120.00 target price (up previously from $108.00) on shares of Insmed in a report on Friday, August 8th. Wells Fargo & Company set a $140.00 price objective on shares of Insmed and gave the company an "overweight" rating in a report on Tuesday. Finally, Leerink Partners lifted their price objective on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, June 10th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $121.71.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $122.00 on Wednesday. The company has a market capitalization of $25.79 billion, a price-to-earnings ratio of -21.37 and a beta of 0.95. Insmed has a 12 month low of $60.40 and a 12 month high of $122.03. The firm's 50-day moving average is $100.45 and its 200 day moving average is $82.92. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%. The business's revenue was up 18.9% compared to the same quarter last year. During the same period last year, the business posted ($1.94) earnings per share. Research analysts predict that Insmed will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 933 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $102.51, for a total value of $95,641.83. Following the sale, the insider directly owned 66,394 shares of the company's stock, valued at approximately $6,806,048.94. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the sale, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 537,440 shares of company stock valued at $50,436,948 over the last 90 days. Insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Insmed

Large investors have recently added to or reduced their stakes in the business. Choreo LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $227,000. Northwest & Ethical Investments L.P. boosted its holdings in shares of Insmed by 226.7% in the 2nd quarter. Northwest & Ethical Investments L.P. now owns 4,900 shares of the biopharmaceutical company's stock valued at $488,000 after buying an additional 3,400 shares in the last quarter. Manchester Capital Management LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $101,000. XTX Topco Ltd boosted its holdings in shares of Insmed by 165.3% in the 2nd quarter. XTX Topco Ltd now owns 56,380 shares of the biopharmaceutical company's stock valued at $5,674,000 after buying an additional 35,130 shares in the last quarter. Finally, Coldstream Capital Management Inc. boosted its holdings in shares of Insmed by 5.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 4,975 shares of the biopharmaceutical company's stock valued at $501,000 after buying an additional 244 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.